Keywords
Abstract
The aim of the study was to study the clinical and laboratory efficacy and safety of etoricoxib in patients with ankylosing spondylitis (AS).
Material and methods. The study included 40 AS patients aged 18 to 55 еars who were treated in the rheumatology department of the multidisciplinary clinic of the Tashkent Medical Academy. Based on the purpose of the study, the patients were divided into two groups: group 1 - 20 patients received etoricoxib 90 mg 1 tab x 1 times after meals, group 2 - 20 patients received Diclofenac 100 mg 1 tab. x 1 times after meals for 12 weeks.
Conclusion. After 12 weeks treatment taking etoricoxib 90 mg/day. and diclofenac 100 mg/day. in 1/3 patients with AS, the activity of sacroiliitis decreased. The frequency of side effects between etoricoxib and diclofenac did not differ significantly.
References
Гайдукова И.З., Ребров А.П., и др. Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. Терапевтический архив. 2014;12:42-47.
Каратеев А.Е. Нестероидные противовоспалительные препараты в современной клинической практике: ≪за≫ больше, чем ≪против≫. Совр ревматол 2008; 1: 70—77.
Baraliakos X., Haibel H., Listing J. et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 еars in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73(4): 710-715.
Braun J., van den Berg R., Baraliakos X. et al. 2010 update of the ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70 (6): 896—904.
Dougados M., van der Heijde D., Sieper J. et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66 (8): 2091-2102.
Maquirriain J., Kokalj A. Management of acute Achilles tendinopathy: effect of etoricoxib on pain control and leg stiffness. Georgian Med News 2013; 222: 36-43.
Patrignani P., Capone M.L., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4 (2): 265-284.
Poddubnyy D., van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am 2012; 38 (3): 601—611.
Poddubnyy D., Rudwaleit M., Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71 (10): 1616—1622.
Poddubnyy D., Haibel H., Listing J. et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012; 64 (5): 1388—1398.
Satoshi Endo, Tsubasa Nishiyama, Tomoe Matuoka et.al. Loxoprofen increases the function of the intestinal barrier by forming active metabolite carbonyl reductase 1 in differentiated Caco-2 cells. Chemico-Biological Interactions. 348 (2021) 109634.
Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-infl ammatory drugs, cyclooxygenase-2 and the bone healing process.Basic Clin Pharmacol Toxicol. 2008;102:10-4. doi: 10.1111/j.1742-7843.2007.00149.x
Wanders A., van der Heijde D., Landewe R. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 1756—1765.